ASX-173
ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC50 = 0.113 μM, Ki = 0.4 nM). ASX-173 enhances the anticancer activity of L-asparaginase (ASNase). ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers[1].
Product Specifications
CAS Number
2748800-08-8
UNSPSC
12352005
Target
Akt; Apoptosis; Atg8/LC3; Autophagy; Caspase; CDK; PARP
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
CC[C@@H](C(N1C[C@@H](C2=CC=C(C=C2)F)[C@H](O)[C@@H]1C(NC(C3=CC=CC=C3)C4=CC=CC=C4)=O)=O)N
Molecular Formula
C28H30FN3O3
Molecular Weight
475.55
References & Citations
[1]Victor Tatarskiy , et al. The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HSP27 (HSPB1/774), CF647 conjugate, 0.1mg/mL
P21 / WAF1 (CIP1/823), Biotin conjugate, 0.1mg/mL
